PO.CL01.15 · 临床研究
侵袭性乳腺癌中NDRG1扩增的转录组学分析
Transcriptomic analysis of NDRG1 amplification in aggressive breast cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:炎性乳腺癌(IBC)是一种罕见但高度侵袭性的乳腺癌变异型,占乳腺癌相关死亡的10%。我们已确定NDRG1(位于8q24.3染色体上,靠近MYC,处于一个常见扩增区域内)是IBC模型中肿瘤生长和进展的关键促进因子,并与不良生存结局相关。与许多癌基因不同,NDRG1很少被缺失或沉默,且在IBC中的表达较非IBC肿瘤更为频繁。近期一项研究报道,在三阴性IBC病例中有42%存在NDRG1扩增。我们假设三阴性IBC中的NDRG1扩增与独特的基因表达谱及致癌通路富集相关,这些共同促成了该疾病的侵袭性表型。
方法:使用DEseq2软件包分析了19例三阴性IBC肿瘤(8例NDRG1扩增,11例非扩增)的RNA测序数据。生成热图以可视化聚类和表达差异。使用Hallmark和KEGG通路数据库进行基因集富集分析(GSEA)。使用公开可用的TCGA和METABRIC乳腺癌数据集评估NDRG1扩增及其与mRNA/蛋白表达和生存结局的关联。
结果。在所分析的19例三阴性肿瘤中,8例(42%)表现出NDRG1扩增,其与RNA表达升高显著相关(p = 0.05)。差异表达分析确定CALCA、RHO、DPYSL5、GPR101、ZIC3和IRS4为上调最显著者,SERPINA6、SCGB3A1、PI3、LRG1、DAPL1、MYEOV为在NDRG1扩增肿瘤中下调最显著者。GSEA揭示了DNA修复、细胞周期、mTOR信号传导和MYC靶标通路的富集,下调的通路包括干扰素γ应答、雌激素应答和NFkB通路。TCGA和METABRIC分析证实,NDRG1扩增与mRNA表达升高(p<0.0001)、蛋白水平升高(p<0.0001)以及总生存更差(p=0.013,TCGA;p=0.0002,METABRIC)相关。
结论:NDRG1扩增标志着三阴性IBC中一个转录上独特的亚群,其富集于增殖和DNA修复通路。这些分子特征凸显了其作为侵袭性疾病生物学标志物的潜力,以及作为进一步机制研究和治疗干预潜在靶点的价值。
查看英文原文 English abstract
Background: Inflammatory breast cancer (IBC) is a rare but highly aggressive variant of breast cancer, accounting for 10% of breast cancer-related deaths. We have identified NDRG1, located on chromosome 8q24.3 near MYC within a commonly amplified region, as a key promoter of tumor growth and progression in IBC models and is associated with poor survival outcomes. Unlike many oncogenes, NDRG1 is rarely deleted or silenced and is more frequently expressed in IBC compared to non-IBC tumors. A recent study reported NDRG1 amplification in 42% of triple-negative IBC cases. We hypothesize that NDRG1 amplification in triple-negative IBC is associated with distinct gene expression profiles and enrichment of oncogenic pathways that contribute to the aggressive phenotype of the disease.
Methods: RNA sequencing data from 19 triple-negative IBC tumors (8 NDRG1 amplified, 11 non-amplified) were analyzed using DEseq2 package. Heatmaps were generated to visualize clustering and expression differences. Gene Set Enrichment Analysis (GSEA) was performed using Hallmark and KEGG pathway databases. Publicly available TCGA and METABRIC breast cancer datasets were used to assess NDRG1 amplification and its association with mRNA/protein expression and survival outcomes.
Results . Among the 19 triple-negative tumors analyzed, 8 (42%) exhibited NDRG1 amplification, which was significantly correlated with increased RNA expression (p = 0.05). Differential expression analysis identified CALCA , RHO , DPYSL5 , GPR101 , ZIC3 , and IRS4 as the most upregulated, and SERPINA6 , SCGB3A1 , PI3 , LRG1 , DAPL1 , MYEOV as the most downregulated in NDRG1 -amplified tumors. GSEA revealed enrichment of DNA repair, cell cycle, mTOR signaling, and MYC target pathways, and downregulated pathways included interferon gamma response, estrogen response and NFkB pathway. TCGA and METABRIC analyses confirmed that NDRG1 amplification correlates with elevated mRNA expression (p<0.0001) and elevate protein levels (p<0.0001) and poorer overall survival (p=0.013, TCGA; p=0.0002, METABRIC).
Conclusions: NDRG1 amplification marks a transcriptionally distinct subset of triple-negative IBC, enriched in proliferative and DNA repair pathways. These molecular features highlight its potential as a biomarker of aggressive disease biology and potential target for further mechanistic investigation and therapeutic intervention.
利益披露 Disclosure
E. S. Villodre, None..
G. Manyam, None..
X. Hu, None..
I. L. Rizzo, None..
L. H. L. Phi, None..
K. H. Tesfamariam, None..
A. Nasrazadani, None..
R. M. Layman, None..
B. Lim, None..
V. Valero, None..
S. Krishnamurthy, None..
J. Wang, None..
X. Wang, None..
N. Ueno, None..
W. A. Woodward, None..
B. G. Debeb, None.